The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Edity is an Israel-based biotechnology company that develops a pre-clinical platform to deliver therapeutic proteins for the treatment of cancer, and genetic disorders.